- Mobi delivers an optimal balance of oxygen output, battery life and
weight for effective therapy wherever people go
- ResMed’s growing COPD portfolio now helps treat people in most
stages of their disease
SAN DIEGO–(BUSINESS WIRE)–lt;a href=”https://twitter.com/search?q=%24RMD&src=ctag” target=”_blank”gt;$RMDlt;/agt; lt;a href=”https://twitter.com/hashtag/COPD?src=hash” target=”_blank”gt;#COPDlt;/agt;–ResMed (NYSE: RMD, ASX: RMD), a leader in respiratory care medical
devices and out-of-hospital care software, today announced that its
premier portable oxygen concentrator, Mobi, is now widely available in
the United States.
Mobi offers an optimal balance of oxygen delivery, weight and battery
life so that millions of people with chronic obstructive pulmonary
disease (COPD) or other chronic diseases can enjoy ResMed-quality oxygen
therapy wherever they go.
“Simply put, Mobi keeps you mobile, which research shows is so important
in terms of helping people with COPD lower
their risk of hospitalization and early death,” said ResMed
Respiratory Care President Richie McHale. “Mobi’s ideal balance of
weight, battery life and oxygen output empowers people to stay active,
and live their lives to the fullest.”
ResMed now offers a wide variety of solutions to help people manage
their COPD at most stages: Mobi for people requiring oxygen therapy,
Astral and AirCurve 10 ST-A devices for cloud-connected in-home
ventilation, for people with severe COPD. Propeller rounds out this
portfolio with mild- to moderate-stage COPD solutions.
“The broad suite of devices ResMed now offers to treat COPD at different
stages is truly life-changing,” McHale said. “But really we’re just
getting started in terms of helping 380 million people with COPD improve
their quality of life, reduce the impact of chronic disease, and lower
healthcare costs,” McHale said.
Mobi will be available in other countries later this year, pending
At ResMed (NYSE: RMD, ASX: RMD) we pioneer innovative solutions that
treat and keep people out of the hospital, empowering them to live
healthier, higher-quality lives. Our cloud-connected medical devices
transform care for people with sleep apnea, COPD and other chronic
diseases. Our comprehensive out-of-hospital software platforms support
the professionals and caregivers who help people stay healthy in the
home or care setting of their choice. By enabling better care, we
improve quality of life, reduce the impact of chronic disease and lower
costs for consumers and healthcare systems in more than 120
countries. To learn more, visit ResMed.com and follow @ResMed.
For media:Jayme Rubenstein+1 858-836-6798[email protected]
For investors:Amy Wakeham+1 858-836-5000[email protected]